Diaceutics PLC (LON:DXRX - Get Free Report) shares traded down 1.6% during mid-day trading on Wednesday . The stock traded as low as GBX 127 ($1.65) and last traded at GBX 127 ($1.65). 5,782 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 111,015 shares. The stock had previously closed at GBX 129 ($1.67).
Analyst Ratings Changes
Separately, Canaccord Genuity Group restated a "buy" rating and issued a GBX 160 ($2.08) price target on shares of Diaceutics in a report on Tuesday, September 17th.
Read Our Latest Analysis on Diaceutics
Diaceutics Trading Down 1.6 %
The business's 50 day simple moving average is GBX 130.60 and its 200 day simple moving average is GBX 123.15. The stock has a market cap of £107.28 million, a price-to-earnings ratio of -4,233.33 and a beta of 0.58. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 2.93.
Diaceutics Company Profile
(
Get Free Report)
Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Diaceutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diaceutics wasn't on the list.
While Diaceutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
